# LT4/LT3 Combination Therapy Versus LT4 Monotherapy in Patients with Autoimmune Hypothyroidism.

> **NCT05682482** · PHASE3 · RECRUITING · sponsor: **M. Medici** · enrollment: 600 (estimated)

## Conditions studied

- Autoimmune Hypothyroidism

## Interventions

- **DRUG:** LT3 (liothyronine)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05682482
- **Lead sponsor:** M. Medici
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-07
- **Primary completion:** 2028-01
- **Final completion:** 2028-01
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2025-02-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05682482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05682482, "LT4/LT3 Combination Therapy Versus LT4 Monotherapy in Patients with Autoimmune Hypothyroidism.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05682482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*